Search Clinical Trials

Durvalumab and Tremelimumab in Treating Patients With Recurrent Stage IV Lung Cancer

Durvalumab Following SBRT for the Treatment of Patients with Stage I/II NSCLC

Evaluation of SAR408701 in Patients With Advanced Solid Tumors

My Pathway: A Study Evaluating Herceptin/Perjeta, Tarceva, Zelboraf/Cotellic, Erivedge, Alecensa, and Tecentriq Treatment Targeted Against Certain Molecular Alterations in Participants With Advanced Solid Tumors

A Trial to Find the Safe Dose for BI 891065 Alone and in Combination With BI 754091 in Patients With Incurable Tumours or Tumours That Have Spread

A Study of TRK-950 in Combinations With Anti-Cancer Treatment Regimens in Patients With Advanced Solid Tumors

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Rucaparib in Patients with Genomic LOH High And/Or Deleterious BRCA1/2 Mutation NSCLC

Targeted Treatment for Advanced Non-Small Cell Lung Cancer

Autologous Tumor Infiltrating Lymphocytes (LN-144 or LN-145) in Patients with Solid Tumors

Researchers have found that sometimes the body’s own immune system may slow down or control cancer growth. Sometimes this natural immune system response stops, and the cancer is not killed by the immune system. Research has shown that, in some patients, cancer cells and immune cells start to express signals that stop the body’s immune system from killing the cancer. New drugs being developed are designed to block these signals and to increase the immune response. Durvalumab and tremelimumab are two of these drugs. Both drugs are antibodies (proteins that are produced by the body’s defense system). Durvalumab given by itself or with tremelimumab may boost the ability of your immune system to detect and fight cancer. Each of these drugs targets a different signal. Durvalumab targets a signal on cancer cells called Programmed Cell Death Ligand 1 (PD-L1) and tremelimumab targets a signal on immune cells called Cytotoxic T-Lymphocyte-associated Antigen 4 (CTLA-4). It is hoped that by blocking these signals, the immune cells will once again be able to prevent or slow down cancer growth.

The vaccine, BI 1361849, also works by stimulating the body’s immune system to fight and destroy cancer cells. There are six different ingredients in the vaccine that each produce a different antibody response to tumor cells. The vaccine is given through an injection into your skin.

Study of Telisotuzumab Vedotin (ABBV-399) in Subjects With Previously Treated c-Met+ Non-Small Cell

The purpose of this study is to compare any good and bad effects of avoiding the hippocampus during whole-brain radiation to the usual whole-brain radiation. The hippocampus is part of the brain that is important for memory. Avoiding the hippocampus during whole-brain radiation could decrease the chance of side effects on memory and thinking. It also is possible that avoiding the hippocampus could have no benefit or could cause other side effects. Hippocampal avoidance also could lessen the effectiveness of whole-brain radiation. This study will allow the researchers to know whether this different approach is better, the same, or worse than the usual approach. To be better, the addition of the hippocampal avoidance technique to whole-brain radiation therapy should decrease the chance of side effects on memory or thinking by at least 14.5%.

This Study Tests the New Medicine BI 754111 Alone or in Combination With Another New Substance BI 754091 in Patients With Advanced Cancer. The Study Tests Different Doses to Find the Best Dose for Continuous Treatment.

Genetic Testing in Screening Patients With Stage IB-IIIA Non-Small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial)